Arcturus Therapeutics Holdings Inc. Share Price
NASDAQ: ARCT | Micro CapArcturus Therapeutics Holdings Inc. Stock Performance
Open $6.73 | Prev. Close $6.08 | Circuit Range N/A |
Day Range $6.46 - $7.55 | Year Range $5.50 - $23.95 | Volume 65,965 |
Average Traded $7.00 |
Arcturus Therapeutics Holdings Inc. Share Price Today
As of 10 August 2026, Arcturus Therapeutics Holdings Inc.'s share price is $7.42. The stock opened at $6.73, compared to its previous close of $6.08. During today's trading session, Arcturus Therapeutics Holdings Inc.'s share price traded between $6.46 and $7.55, with an average price of $7.01. Over the past 52 weeks, the stock has recorded a high of $23.95 and a low of $5.50. In terms of performance, Arcturus Therapeutics Holdings Inc.'s share price has declined by 10.06% over the last six months and is down 56.43% on a year-on-year basis.
Arcturus Therapeutics Holdings Inc. Share Price Chart
Arcturus Therapeutics Holdings Inc. Stock Fundamentals & Key Indicators
Market Cap $203.20M | PE Ratio (TTM) -3.09 | Dividend Yield N/A |
EPS (TTM) $-2.40 | Revenue (TTM) $82.03M | Return On Equity (TTM) -30.74% |
Profit Margin -80.19% | Debt to Equity 0.17 | Quarterly Earnings Growth YoY N/A |
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Holdings Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $5.86 | $7.41 | +28.76% |
Jul 2026 | $6.83 | $5.75 | -14.23% |
Jun 2026 | $7.71 | $6.71 | -15.49% |
May 2026 | $8.54 | $7.94 | -7.89% |
Apr 2026 | $7.99 | $8.62 | +11.51% |
Mar 2026 | $8.07 | $7.73 | -6.30% |
Feb 2026 | $7.37 | $8.25 | +10.15% |
Jan 2026 | $6.19 | $7.49 | +22.59% |
Dec 2025 | $6.47 | $6.11 | -9.75% |
Nov 2025 | $10.04 | $6.77 | -32.23% |
Oct 2025 | $19.16 | $9.99 | -45.82% |
Sep 2025 | $17.09 | $18.44 | +8.28% |
ARCT Share Price FAQs
What is Arcturus Therapeutics Holdings Inc. share price today?
What is the 52 week high and 52 week low of Arcturus Therapeutics Holdings Inc. stock?
What is ARCT's market capitalisation today?
What is the 5 year returns of ARCT?
What is the high & low stock price of ARCT today?
Can I buy ARCT shares in India?